Contact
searchSearch
HMP Global
Login

Non-Small Cell Lung Cancer Resource Center

Conference Coverage
Patient-Centered Insights into Treatment Preferences for Locally Advanced and Metastatic NSCLC
03/28/2025
Juliet Gallagher
New research presented at the 2025 National Comprehensive Cancer Network (NCCN) Annual Conference sheds light on how patients with advanced or metastatic non-small cell lung cancer (aNSCLC or mNSCLC) approach treatment decision-making,...
New research presented at the 2025 National Comprehensive Cancer Network (NCCN) Annual Conference sheds light on how patients with advanced or metastatic non-small cell lung cancer (aNSCLC or mNSCLC) approach treatment decision-making,...
New research presented at the...
03/28/2025
Journal of Clinical Pathways
News
Radiomics and AI Advance NSCLC Staging Precision
03/10/2025
Juliet Gallagher
A recent study published in Cancers explores the potential of artificial intelligence (AI) to enhance the preliminary staging of non-small cell lung cancer (NSCLC) using computed tomography (CT) imaging.
A recent study published in Cancers explores the potential of artificial intelligence (AI) to enhance the preliminary staging of non-small cell lung cancer (NSCLC) using computed tomography (CT) imaging.
A recent study published in...
03/10/2025
Journal of Clinical Pathways
News
Machine Learning Identifies Key Genomic Markers to Predict CPI Outcomes in NSCLC
03/06/2025
Grace Taylor, MS, MA
A machine learning-driven study analyzing genomic data from patients with non-small cell lung cancer (NSCLC) reveals specific mutations and pathways that influence resistance to checkpoint inhibitor immunotherapy, offering potential targets...
A machine learning-driven study analyzing genomic data from patients with non-small cell lung cancer (NSCLC) reveals specific mutations and pathways that influence resistance to checkpoint inhibitor immunotherapy, offering potential targets...
A machine learning-driven study...
03/06/2025
Journal of Clinical Pathways
News
Evaluating Cost-Effectiveness of First-Line Cemiplimab Therapy in Advanced NSCLC
03/05/2025
Juliet Gallagher
A recent cost-effectiveness analysis published in Journal of Managed Care & Specialty Pharmacy comparing cemiplimab plus chemotherapy (CCT) with pembrolizumab plus chemotherapy (PCT) as first-line treatment for advanced non-small cell lung...
A recent cost-effectiveness analysis published in Journal of Managed Care & Specialty Pharmacy comparing cemiplimab plus chemotherapy (CCT) with pembrolizumab plus chemotherapy (PCT) as first-line treatment for advanced non-small cell lung...
A recent cost-effectiveness...
03/05/2025
Journal of Clinical Pathways
News
Durvalumab Immunotherapy Shows Survival Benefit but Fails Cost-Effectiveness in Key Markets
02/13/2025
Lisa Kuhns, PhD, MD
Durvalumab immunotherapy improves survival in unresectable stage III non-small cell lung cancer (NSCLC), but its high cost makes it prohibitive globally under current pricing models, according to study results published in JAMA Network Open.
Durvalumab immunotherapy improves survival in unresectable stage III non-small cell lung cancer (NSCLC), but its high cost makes it prohibitive globally under current pricing models, according to study results published in JAMA Network Open.
Durvalumab immunotherapy...
02/13/2025
Journal of Clinical Pathways
News
Machine Learning Algorithms Offer Alternative to Imaging in NSCLC Staging
02/03/2025
Juliet Gallagher
A recent study published in Journal of Thoracic Disease demonstrated the effectiveness of artificial intelligence (AI) in predicting lymph node metastasis in patients with non-small cell lung cancer (NSCLC).
A recent study published in Journal of Thoracic Disease demonstrated the effectiveness of artificial intelligence (AI) in predicting lymph node metastasis in patients with non-small cell lung cancer (NSCLC).
A recent study published in...
02/03/2025
Journal of Clinical Pathways
News
Artificial Intelligence Predicts Survival Outcomes in Advanced NSCLC
01/21/2025
Juliet Gallagher
A recent study published in BMC Cancer developed an artificial intelligence (AI)-based model to predict survival outcomes for patients with advanced non-small cell lung cancer (NSCLC), offering a step forward in personalized medicine.
A recent study published in BMC Cancer developed an artificial intelligence (AI)-based model to predict survival outcomes for patients with advanced non-small cell lung cancer (NSCLC), offering a step forward in personalized medicine.
A recent study published in BMC...
01/21/2025
Journal of Clinical Pathways
News
Neratinib Demonstrates Promising Efficacy for Patients With EGFR-Mutated Non-Small Cell Lung Cancer
01/08/2025
Stephanie Holland
According to results from the phase 2 SUMMIT basket trial, neratinib demonstrated promising efficacy among patients with EGFR-mutated non-small cell lung cancer.
According to results from the phase 2 SUMMIT basket trial, neratinib demonstrated promising efficacy among patients with EGFR-mutated non-small cell lung cancer.
According to results from the...
01/08/2025
Oncology
From Oncology
News
FDA Approved Lazertinib Plus Amivantamab for Advanced Non-Small Cell Lung Cancer With EGFR Mutations
08/20/2024
Allison Casey
The FDA has approved lazertinib plus amivantamab for adult patients with locally advanced or metastatic non-small cell lung cancer with EGFR exon 19 deletions or exon 21 L858R substitution mutations.
The FDA has approved lazertinib plus amivantamab for adult patients with locally advanced or metastatic non-small cell lung cancer with EGFR exon 19 deletions or exon 21 L858R substitution mutations.
The FDA has approved lazertinib...
08/20/2024
Oncology
From Oncology
News
FDA Grants Approval to Neoadjuvant/Adjuvant Durvalumab for Patients With Resectable Non-Small Cell Lung Cancer
08/16/2024
Stephanie Holland
The FDA has approved durvalumab plus a platinum-containing regimen followed by surgery and single-agent durvalumab for adult patients with resectable non-small cell lung cancer with no known EGFR mutations or ALK rearrangements.
The FDA has approved durvalumab plus a platinum-containing regimen followed by surgery and single-agent durvalumab for adult patients with resectable non-small cell lung cancer with no known EGFR mutations or ALK rearrangements.
The FDA has approved durvalumab...
08/16/2024
Oncology
From Oncology
News
Osimertinib Lacks Activity in Neoadjuvant Setting for Early-Stage Non-Small Cell Lung Cancer With EGFR Mutation
08/08/2024
Stephanie Holland
Results from a phase 2 study demonstrated that neoadjuvant osimertinib did not improve the major pathological response rate among patients with early-stage non-small cell lung cancer harboring an EGFR mutation.
Results from a phase 2 study demonstrated that neoadjuvant osimertinib did not improve the major pathological response rate among patients with early-stage non-small cell lung cancer harboring an EGFR mutation.
Results from a phase 2 study...
08/08/2024
Oncology
From Oncology

Expert Insights

Sarah Smith, Virginia Cancer Specialists
Videos
Post-Progression and Safety Outcomes With First-Line Amivantamab Plus Lazertinib vs Osimertinib for Advanced NSCLC: Best Management Practices
05/24/2024
Sarah Smith, BD, CNMT, discusses findings from the phase 3 MARIPOSA study exploring post-progression and safety outcomes with first-line amivantamab plus lazertinib vs osimertinib for advanced NSCLC and offers guidance for best management...
Sarah Smith, BD, CNMT, discusses findings from the phase 3 MARIPOSA study exploring post-progression and safety outcomes with first-line amivantamab plus lazertinib vs osimertinib for advanced NSCLC and offers guidance for best management...
Sarah Smith, BD, CNMT, discusses...
05/24/2024
Oncology
David Waterhouse, MD.
Videos
Increasing Biomarker Testing Rates for Patients With NSCLC
12/07/2023
David Waterhouse, MD, MPH
David Waterhouse, MD, MPH, talks about OHC’s quality improvement project that increased biomarker testing rates for patients with metastatic NSCLC, and shared how the program can be scaled to other practices and other cancers.
David Waterhouse, MD, MPH, talks about OHC’s quality improvement project that increased biomarker testing rates for patients with metastatic NSCLC, and shared how the program can be scaled to other practices and other cancers.
David Waterhouse, MD, MPH, talks...
12/07/2023
Journal of Clinical Pathways
Thomas Stricker, MD.
Videos
Clinical Value of Timely Targeted Therapy for Patients With Advanced Non–Small Cell Lung Cancer
07/12/2023
Thomas Stricker, MD
Thomas Stricker, MD, PhD, speaks with the Journal of Clinical Pathways about his research on the clinical impact of the timing of first line targeted therapy in aNSCLC patients with actionable driver oncogenes.
Thomas Stricker, MD, PhD, speaks with the Journal of Clinical Pathways about his research on the clinical impact of the timing of first line targeted therapy in aNSCLC patients with actionable driver oncogenes.
Thomas Stricker, MD, PhD, speaks...
07/12/2023
Journal of Clinical Pathways
Janet Espirito, PharmD.
Videos
Real-World Response Endpoints in Patients With mNSCLC Treated With Chemotherapy Across Real-World Datasets
07/03/2023
Janet Espirito, PharmD
Janet L. Espirito, PharmD, Senior Medical Director for Ontada, speaks with the Journal of Clinical Pathways about the significance of her research on real-world response endpoints in patients with mNSCLC treated with chemotherapy across...
Janet L. Espirito, PharmD, Senior Medical Director for Ontada, speaks with the Journal of Clinical Pathways about the significance of her research on real-world response endpoints in patients with mNSCLC treated with chemotherapy across...
Janet L. Espirito, PharmD,...
07/03/2023
Journal of Clinical Pathways
Gregory Vidal, MD, Phd
Conference Coverage
Inequities in Next-Generation Sequencing Testing Among Patients With Advanced Non–Small Cell Lung Cancer
06/07/2023
Dr Gregory Vidal, Breast Medical Oncologist, West Cancer Center, Germantown, TN, spoke with the Journal of Clinical Pathways at the ASCO 2023 Annual Meeting about his study on inequities in next-generation sequencing testing by race/ethnicity...
Dr Gregory Vidal, Breast Medical Oncologist, West Cancer Center, Germantown, TN, spoke with the Journal of Clinical Pathways at the ASCO 2023 Annual Meeting about his study on inequities in next-generation sequencing testing by race/ethnicity...
Dr Gregory Vidal, Breast Medical...
06/07/2023
Journal of Clinical Pathways
Tejas Patil, MD, University of Colorado Cancer Center
Videos
Utilizing Clinical Pathways in the Treatment of Patients With ALK-Positive NSCLC
04/14/2023
Tejas Patil, MD, University of Colorado Cancer Center, discusses recent developments in the treatment landscape for patients with ALK-positive NSCLC and how clinical pathways can help standardize the treatment practices for these patients.
Tejas Patil, MD, University of Colorado Cancer Center, discusses recent developments in the treatment landscape for patients with ALK-positive NSCLC and how clinical pathways can help standardize the treatment practices for these patients.
Tejas Patil, MD, University of...
04/14/2023
Journal of Clinical Pathways
Janet Espirito, PharmD
Videos
Integrating Biomarker Testing Into Clinical Pathways to Optimize the NSCLC Treatment Landscape
11/03/2022
Janet Espirito, PharmD, discusses the importance of education, awareness of technology, and support for providers and patients to utilize comprehensive testing so that patients can receive the proper treatment at the right time.
Janet Espirito, PharmD, discusses the importance of education, awareness of technology, and support for providers and patients to utilize comprehensive testing so that patients can receive the proper treatment at the right time.
Janet Espirito, PharmD,...
11/03/2022
Journal of Clinical Pathways
Nicholas Robert, MD
Videos
Identifying Predictors of Biomarker Testing in Metastatic Non-Small Cell Lung Cancer
07/05/2022
Nicholas Robert, MD, discusses real-world biomarker testing rates for metastatic non–small cell lung cancer within The US Oncology Network, examining patient factors associated with rates of biomarker testing.
Nicholas Robert, MD, discusses real-world biomarker testing rates for metastatic non–small cell lung cancer within The US Oncology Network, examining patient factors associated with rates of biomarker testing.
Nicholas Robert, MD, discusses...
07/05/2022
Journal of Clinical Pathways
Geoffrey Oxnard, MD
Videos
Real-World Testing and Treatment Patterns in Advanced NSCLC
10/18/2021
Geoffrey Oxnard, MD, compares treatment regimens for patients with advanced NSCLC prior to receipt of comprehensive genomic profiling vs after receipt of comprehensive genomic profiling in the real-world setting.
Geoffrey Oxnard, MD, compares treatment regimens for patients with advanced NSCLC prior to receipt of comprehensive genomic profiling vs after receipt of comprehensive genomic profiling in the real-world setting.
Geoffrey Oxnard, MD, compares...
10/18/2021
Journal of Clinical Pathways
Videos
Cost-Effectiveness of Adjuvant Osimertinib for EGFR-Mutant NSCLC
07/01/2021
Christopher Lemmon, MD, discusses results from a study on the cost-effectiveness of adjuvant osimertinib in resected EGFR mutant NSCLC patients, finding that it may have the potential to be cost-effective, given the right financial...
Christopher Lemmon, MD, discusses results from a study on the cost-effectiveness of adjuvant osimertinib in resected EGFR mutant NSCLC patients, finding that it may have the potential to be cost-effective, given the right financial...
Christopher Lemmon, MD,...
07/01/2021
Journal of Clinical Pathways
Houda Hachad, PharmD
Interview
FDA Highlights Risks Associated With DPD Deficiency, Advises Testing Before Treatment
03/26/2025
Houda Hachad, PharmD
This interview explores the US Food and Drug Administration’s (FDA) updated guidance on dihydropyrimidine dehydrogenase (DPD) deficiency and its implications for improving patient safety through pre-treatment DPYD testing before...
This interview explores the US Food and Drug Administration’s (FDA) updated guidance on dihydropyrimidine dehydrogenase (DPD) deficiency and its implications for improving patient safety through pre-treatment DPYD testing before...
This interview explores the US...
03/26/2025
Journal of Clinical Pathways
Upal Basu Roy, PhD, MPH
Interview
Project PRIORITY: Elevating the Patient Voice in EGFR-Positive NSCLC Care
03/24/2025
Upal Basu Roy, PhD, MPH
In this interview, Upal Basu Roy, PhD, MPH, shares how by centering on patient experiences, Project PRIORITY reveals critical disparities in access to diagnostics, treatment, and palliative care for patients with epidermal growth factor...
In this interview, Upal Basu Roy, PhD, MPH, shares how by centering on patient experiences, Project PRIORITY reveals critical disparities in access to diagnostics, treatment, and palliative care for patients with epidermal growth factor...
In this interview, Upal Basu...
03/24/2025
Journal of Clinical Pathways
Videos
Why Pathways Matter: Editorial Advisory Board Testimonials
03/24/2025
F. Randy Vogenberg, PhD, FASHP
For the past 10 years, Journal of Clinical Pathways has been at the forefront of advancing evidence-based, value-driven care through clinical pathways. As we celebrate our 10th anniversary, we’re highlighting the voices of key thought leaders...
For the past 10 years, Journal of Clinical Pathways has been at the forefront of advancing evidence-based, value-driven care through clinical pathways. As we celebrate our 10th anniversary, we’re highlighting the voices of key thought leaders...
For the past 10 years, Journal...
03/24/2025
Journal of Clinical Pathways
Kohli Headshot
Interview
Strengthening Patient Pathways With BIS for Lymphedema Surveillance
03/24/2025
Manpreet Kohli, MD
In this interview, Manpreet Kohli, MD, discusses the incorporation of bioimpedance spectroscopy into NAPBC standards, the impact of early lymphedema detection on survivorship, and how clinicians can better support patient-centered care...
In this interview, Manpreet Kohli, MD, discusses the incorporation of bioimpedance spectroscopy into NAPBC standards, the impact of early lymphedema detection on survivorship, and how clinicians can better support patient-centered care...
In this interview, Manpreet...
03/24/2025
Journal of Clinical Pathways
Chelsea Renfro, PharmD
Interview
How Integrated Health System Pharmacies Enhance Treatment Adherence and Adverse Effect Management for CLL
03/21/2025
Houston Wyatt, PharmD; Chelsea E. Renfro, PharmD; Stephanie White, PharmD
This interview explores how integrated health system pharmacy services can improve medication adherence, persistence, and adverse effect management in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL).
This interview explores how integrated health system pharmacy services can improve medication adherence, persistence, and adverse effect management in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL).
This interview explores how...
03/21/2025
Journal of Clinical Pathways
Videos
Progress and Unmet Needs in Post-IO Treatment for Metastatic RCC
03/19/2025
Neil Shah, MD
In this interview, Dr Neil Shah discusses the challenges of treatment sequencing for metastatic renal cell carcinoma (mRCC) after immune checkpoint inhibitor therapy, highlighting findings from his study on post-IO treatment efficacy and the...
In this interview, Dr Neil Shah discusses the challenges of treatment sequencing for metastatic renal cell carcinoma (mRCC) after immune checkpoint inhibitor therapy, highlighting findings from his study on post-IO treatment efficacy and the...
In this interview, Dr Neil Shah...
03/19/2025
Journal of Clinical Pathways
Graf Headshot
Interview
The Future of Chronic Lymphocytic Leukemia Management with Targeted Therapies
03/17/2025
In this interview, an expert discusses the preclinical development and clinical impact of zanubrutinib in chronic lymphocytic leukemia, highlighting key findings from pivotal trials, comparisons with other therapies, and future research...
In this interview, an expert discusses the preclinical development and clinical impact of zanubrutinib in chronic lymphocytic leukemia, highlighting key findings from pivotal trials, comparisons with other therapies, and future research...
In this interview, an expert...
03/17/2025
Journal of Clinical Pathways
Oncology Innovations
Videos
Advancing Value-Based Oncology With the Predictable Cost of Care Working Group: Part 2
03/17/2025
Gordon Kuntz; Carole Tremonti, RN, MBA
In this episode of Oncology Innovations, experts discuss the Predictable Cost of Care Working Group’s efforts to develop a standardized model for assessing oncology treatment costs, highlighting insights from phase I, the goals of phase II,...
In this episode of Oncology Innovations, experts discuss the Predictable Cost of Care Working Group’s efforts to develop a standardized model for assessing oncology treatment costs, highlighting insights from phase I, the goals of phase II,...
In this episode of Oncology...
03/17/2025
Journal of Clinical Pathways
Brian S.
Interview
Key Advancements in Immunotherapy for Endometrial Cancer
03/13/2025
Brian M. Slomovitz, MD, MS
A guest expert discusses groundbreaking research on pembrolizumab in adjuvant treatment for endometrial cancer, highlighting the significant impact on reducing recurrence risk in patients with deficient mismatch repair and the need for...
A guest expert discusses groundbreaking research on pembrolizumab in adjuvant treatment for endometrial cancer, highlighting the significant impact on reducing recurrence risk in patients with deficient mismatch repair and the need for...
A guest expert discusses...
03/13/2025
Journal of Clinical Pathways
Brufsky Headshot
Interview
Transforming Metastatic Breast Cancer Care With AI and Real-World Evidence
03/11/2025
Adam Brufsky, MD, PhD
In this interview, Adam Brufsky, MD, PhD, discusses the evolving treatment landscape for hormone receptor-positive/HER2-negative metastatic breast cancer, the impact of CDK4/6 inhibitors, the role of genomic assays and artificial intelligence...
In this interview, Adam Brufsky, MD, PhD, discusses the evolving treatment landscape for hormone receptor-positive/HER2-negative metastatic breast cancer, the impact of CDK4/6 inhibitors, the role of genomic assays and artificial intelligence...
In this interview, Adam Brufsky,...
03/11/2025
Journal of Clinical Pathways

Newsfeed

Conference Coverage
Patient-Centered Insights into Treatment Preferences for Locally Advanced and Metastatic NSCLC
03/28/2025
Juliet Gallagher
New research presented at the 2025 National Comprehensive Cancer Network (NCCN) Annual Conference sheds light on how patients with advanced or metastatic non-small cell lung cancer (aNSCLC or mNSCLC) approach treatment decision-making,...
New research presented at the 2025 National Comprehensive Cancer Network (NCCN) Annual Conference sheds light on how patients with advanced or metastatic non-small cell lung cancer (aNSCLC or mNSCLC) approach treatment decision-making,...
New research presented at the...
03/28/2025
Journal of Clinical Pathways
News
Radiomics and AI Advance NSCLC Staging Precision
03/10/2025
Juliet Gallagher
A recent study published in Cancers explores the potential of artificial intelligence (AI) to enhance the preliminary staging of non-small cell lung cancer (NSCLC) using computed tomography (CT) imaging.
A recent study published in Cancers explores the potential of artificial intelligence (AI) to enhance the preliminary staging of non-small cell lung cancer (NSCLC) using computed tomography (CT) imaging.
A recent study published in...
03/10/2025
Journal of Clinical Pathways
News
Machine Learning Identifies Key Genomic Markers to Predict CPI Outcomes in NSCLC
03/06/2025
Grace Taylor, MS, MA
A machine learning-driven study analyzing genomic data from patients with non-small cell lung cancer (NSCLC) reveals specific mutations and pathways that influence resistance to checkpoint inhibitor immunotherapy, offering potential targets...
A machine learning-driven study analyzing genomic data from patients with non-small cell lung cancer (NSCLC) reveals specific mutations and pathways that influence resistance to checkpoint inhibitor immunotherapy, offering potential targets...
A machine learning-driven study...
03/06/2025
Journal of Clinical Pathways
News
Evaluating Cost-Effectiveness of First-Line Cemiplimab Therapy in Advanced NSCLC
03/05/2025
Juliet Gallagher
A recent cost-effectiveness analysis published in Journal of Managed Care & Specialty Pharmacy comparing cemiplimab plus chemotherapy (CCT) with pembrolizumab plus chemotherapy (PCT) as first-line treatment for advanced non-small cell lung...
A recent cost-effectiveness analysis published in Journal of Managed Care & Specialty Pharmacy comparing cemiplimab plus chemotherapy (CCT) with pembrolizumab plus chemotherapy (PCT) as first-line treatment for advanced non-small cell lung...
A recent cost-effectiveness...
03/05/2025
Journal of Clinical Pathways
News
Durvalumab Immunotherapy Shows Survival Benefit but Fails Cost-Effectiveness in Key Markets
02/13/2025
Lisa Kuhns, PhD, MD
Durvalumab immunotherapy improves survival in unresectable stage III non-small cell lung cancer (NSCLC), but its high cost makes it prohibitive globally under current pricing models, according to study results published in JAMA Network Open.
Durvalumab immunotherapy improves survival in unresectable stage III non-small cell lung cancer (NSCLC), but its high cost makes it prohibitive globally under current pricing models, according to study results published in JAMA Network Open.
Durvalumab immunotherapy...
02/13/2025
Journal of Clinical Pathways
News
Machine Learning Algorithms Offer Alternative to Imaging in NSCLC Staging
02/03/2025
Juliet Gallagher
A recent study published in Journal of Thoracic Disease demonstrated the effectiveness of artificial intelligence (AI) in predicting lymph node metastasis in patients with non-small cell lung cancer (NSCLC).
A recent study published in Journal of Thoracic Disease demonstrated the effectiveness of artificial intelligence (AI) in predicting lymph node metastasis in patients with non-small cell lung cancer (NSCLC).
A recent study published in...
02/03/2025
Journal of Clinical Pathways
News
Artificial Intelligence Predicts Survival Outcomes in Advanced NSCLC
01/21/2025
Juliet Gallagher
A recent study published in BMC Cancer developed an artificial intelligence (AI)-based model to predict survival outcomes for patients with advanced non-small cell lung cancer (NSCLC), offering a step forward in personalized medicine.
A recent study published in BMC Cancer developed an artificial intelligence (AI)-based model to predict survival outcomes for patients with advanced non-small cell lung cancer (NSCLC), offering a step forward in personalized medicine.
A recent study published in BMC...
01/21/2025
Journal of Clinical Pathways
News
Neratinib Demonstrates Promising Efficacy for Patients With EGFR-Mutated Non-Small Cell Lung Cancer
01/08/2025
Stephanie Holland
According to results from the phase 2 SUMMIT basket trial, neratinib demonstrated promising efficacy among patients with EGFR-mutated non-small cell lung cancer.
According to results from the phase 2 SUMMIT basket trial, neratinib demonstrated promising efficacy among patients with EGFR-mutated non-small cell lung cancer.
According to results from the...
01/08/2025
Oncology
News
FDA Approved Lazertinib Plus Amivantamab for Advanced Non-Small Cell Lung Cancer With EGFR Mutations
08/20/2024
Allison Casey
The FDA has approved lazertinib plus amivantamab for adult patients with locally advanced or metastatic non-small cell lung cancer with EGFR exon 19 deletions or exon 21 L858R substitution mutations.
The FDA has approved lazertinib plus amivantamab for adult patients with locally advanced or metastatic non-small cell lung cancer with EGFR exon 19 deletions or exon 21 L858R substitution mutations.
The FDA has approved lazertinib...
08/20/2024
Oncology
News
FDA Grants Approval to Neoadjuvant/Adjuvant Durvalumab for Patients With Resectable Non-Small Cell Lung Cancer
08/16/2024
Stephanie Holland
The FDA has approved durvalumab plus a platinum-containing regimen followed by surgery and single-agent durvalumab for adult patients with resectable non-small cell lung cancer with no known EGFR mutations or ALK rearrangements.
The FDA has approved durvalumab plus a platinum-containing regimen followed by surgery and single-agent durvalumab for adult patients with resectable non-small cell lung cancer with no known EGFR mutations or ALK rearrangements.
The FDA has approved durvalumab...
08/16/2024
Oncology
Conference Coverage
Delayed EGFR Testing in Early-Stage NSCLC Linked to Increased Health Care Utilization and Cost Burden
04/01/2025
Juliet Gallagher
Timely molecular testing is essential for guiding targeted treatment in patients with early-stage non-small cell lung cancer (eNSCLC), particularly those with EGFR mutations. Findings presented at the 2025 National Comprehensive Cancer...
Timely molecular testing is essential for guiding targeted treatment in patients with early-stage non-small cell lung cancer (eNSCLC), particularly those with EGFR mutations. Findings presented at the 2025 National Comprehensive Cancer...
Timely molecular testing is...
04/01/2025
Journal of Clinical Pathways
Conference Coverage
Study Explores Early Palliative Care Referral Patterns and Outcomes in SCLC
04/01/2025
Juliet Gallagher
At the 2025 National Comprehensive Cancer Network (NCCN) Annual Conference, researchers presented findings from a retrospective study evaluating timing of palliative care referral and associated outcomes among patients with small cell lung...
At the 2025 National Comprehensive Cancer Network (NCCN) Annual Conference, researchers presented findings from a retrospective study evaluating timing of palliative care referral and associated outcomes among patients with small cell lung...
At the 2025 National...
04/01/2025
Journal of Clinical Pathways
Conference Coverage
EHR-Embedded CDS Tool Enhances Specialty Drug Management in Oncology
03/28/2025
Juliet Gallagher
A retrospective study presented at the 2025 National Comprehensive Cancer Network (NCCN) Annual Conference evaluated how embedding a clinical decision support (CDS) tool within the electronic health record (EHR) can enhance specialty drug...
A retrospective study presented at the 2025 National Comprehensive Cancer Network (NCCN) Annual Conference evaluated how embedding a clinical decision support (CDS) tool within the electronic health record (EHR) can enhance specialty drug...
A retrospective study presented...
03/28/2025
Journal of Clinical Pathways
Conference Coverage
Patient-Centered Insights into Treatment Preferences for Locally Advanced and Metastatic NSCLC
03/28/2025
Juliet Gallagher
New research presented at the 2025 National Comprehensive Cancer Network (NCCN) Annual Conference sheds light on how patients with advanced or metastatic non-small cell lung cancer (aNSCLC or mNSCLC) approach treatment decision-making,...
New research presented at the 2025 National Comprehensive Cancer Network (NCCN) Annual Conference sheds light on how patients with advanced or metastatic non-small cell lung cancer (aNSCLC or mNSCLC) approach treatment decision-making,...
New research presented at the...
03/28/2025
Journal of Clinical Pathways
News
Academic Cancer Centers Improve Outcomes for Patients With Mantle Cell Lymphoma
03/18/2025
Lisa Kuhns, PhD, MD
Patients with mantle cell lymphoma (MCL) who receive treatment at academic cancer centers experience longer overall survival and higher participation in clinical trials compared to those treated in community-based practices, according to a...
Patients with mantle cell lymphoma (MCL) who receive treatment at academic cancer centers experience longer overall survival and higher participation in clinical trials compared to those treated in community-based practices, according to a...
Patients with mantle cell...
03/18/2025
Journal of Clinical Pathways
News
Improving Health Care Access for Immigrants With Disabilities in North America
03/14/2025
Hannah Musick
Exploring the barriers and facilitators of immigrants with disabilities accessing health care in the US and Canada, this qualitative meta-synthesis reveals the structural and cultural obstacles faced by this marginalized population and calls...
Exploring the barriers and facilitators of immigrants with disabilities accessing health care in the US and Canada, this qualitative meta-synthesis reveals the structural and cultural obstacles faced by this marginalized population and calls...
Exploring the barriers and...
03/14/2025
Journal of Clinical Pathways
News
AI Revolutionizes Early Detection and Diagnosis of Gastric Cancer
03/14/2025
Lisa Kuhns, PhD, MD
Artificial intelligence (AI) is rapidly transforming the landscape of early gastric cancer (EGC) detection and treatment, offering promising solutions to improve diagnostic accuracy, treatment planning, and patient outcomes, according to an...
Artificial intelligence (AI) is rapidly transforming the landscape of early gastric cancer (EGC) detection and treatment, offering promising solutions to improve diagnostic accuracy, treatment planning, and patient outcomes, according to an...
Artificial intelligence (AI) is...
03/14/2025
Journal of Clinical Pathways
News
Oral JAK2 Inhibitor Offers a Viable Second-Line Treatment for Myelofibrosis, but Challenges Remain
03/13/2025
Lisa Kuhns, PhD, MD
Fedratinib, an oral JAK2 inhibitor, has demonstrated efficacy in treating myelofibrosis (MF), particularly in patients who have failed ruxolitinib therapy, according to a study published in the Blood Cancer Journal.
Fedratinib, an oral JAK2 inhibitor, has demonstrated efficacy in treating myelofibrosis (MF), particularly in patients who have failed ruxolitinib therapy, according to a study published in the Blood Cancer Journal.
Fedratinib, an oral JAK2...
03/13/2025
Journal of Clinical Pathways
News
Early Measurable Residual Disease Assessment Predicts Survival in Patients With Mantle Cell Lymphoma
03/12/2025
Lisa Kuhns, PhD, MD
Patients with mantle cell lymphoma (MCL) can benefit from measurable residual disease (MRD) assessment during induction therapy, with the timing and kinetics of MRD negativity significantly impacting prognosis and treatment strategies,...
Patients with mantle cell lymphoma (MCL) can benefit from measurable residual disease (MRD) assessment during induction therapy, with the timing and kinetics of MRD negativity significantly impacting prognosis and treatment strategies,...
Patients with mantle cell...
03/12/2025
Journal of Clinical Pathways
News
Radiomics and AI Advance NSCLC Staging Precision
03/10/2025
Juliet Gallagher
A recent study published in Cancers explores the potential of artificial intelligence (AI) to enhance the preliminary staging of non-small cell lung cancer (NSCLC) using computed tomography (CT) imaging.
A recent study published in Cancers explores the potential of artificial intelligence (AI) to enhance the preliminary staging of non-small cell lung cancer (NSCLC) using computed tomography (CT) imaging.
A recent study published in...
03/10/2025
Journal of Clinical Pathways

Interactive Features

Conference Coverage
Patient-Centered Insights into Treatment Preferences for Locally Advanced and Metastatic NSCLC
03/28/2025
Juliet Gallagher
New research presented at the 2025 National Comprehensive Cancer Network (NCCN) Annual Conference sheds light on how patients with advanced or metastatic non-small cell lung cancer (aNSCLC or mNSCLC) approach treatment decision-making,...
New research presented at the 2025 National Comprehensive Cancer Network (NCCN) Annual Conference sheds light on how patients with advanced or metastatic non-small cell lung cancer (aNSCLC or mNSCLC) approach treatment decision-making,...
New research presented at the...
03/28/2025
Journal of Clinical Pathways
News
Impact of Care Delays on Health Care Resource Utilization in Patients With Early-Stage Lung Cancer
06/26/2024

Brandon Twyford

Brandon Twyford
Researchers conducted a study on the real-world ramifications of delayed surgical intervention in early-stage non–small cell lung cancer, highlighting the complex relationship between timing of surgery, patient outcomes, and health care...
Researchers conducted a study on the real-world ramifications of delayed surgical intervention in early-stage non–small cell lung cancer, highlighting the complex relationship between timing of surgery, patient outcomes, and health care...
Researchers conducted a study on...
06/26/2024
Journal of Clinical Pathways
News
Tracking Cost of Care Discussions Between Physicians and Patients with NSCLC and Melanoma
10/30/2023
Grace Taylor, MS, MA
Robin Yabroff, PhD, MBA, and Michael T. Halpern, MD, PhD, MPH, examine the documentation of cost of care discussions between physicians and patients with non–small cell lung cancer and melanoma.
Robin Yabroff, PhD, MBA, and Michael T. Halpern, MD, PhD, MPH, examine the documentation of cost of care discussions between physicians and patients with non–small cell lung cancer and melanoma.
Robin Yabroff, PhD, MBA, and...
10/30/2023
Journal of Clinical Pathways
News
New Dimensions in Comprehensive Genomic Testing
10/17/2023
Grace Taylor, MS, MA
Eric Severson, MD, PhD, Labcorp Oncology, examines genomic testing’s role in comprehensive oncology pathways.
Eric Severson, MD, PhD, Labcorp Oncology, examines genomic testing’s role in comprehensive oncology pathways.
Eric Severson, MD, PhD, Labcorp...
10/17/2023
Journal of Clinical Pathways
Conference Coverage
Research Shows that Health Care Costs Vary Based on HIC Status in Patients With NSCLC
06/13/2023
Emry Lloyd
In an abstract presented at ASCO 2023, researchers compared real-world data on health care costs for HIC-H and HIC-C patients with NSCLC before and after they received the HIC test.
In an abstract presented at ASCO 2023, researchers compared real-world data on health care costs for HIC-H and HIC-C patients with NSCLC before and after they received the HIC test.
In an abstract presented at ASCO...
06/13/2023
Journal of Clinical Pathways
Gregory Vidal, MD, Phd
Conference Coverage
Inequities in Next-Generation Sequencing Testing Among Patients With Advanced Non–Small Cell Lung Cancer
06/07/2023
Dr Gregory Vidal, Breast Medical Oncologist, West Cancer Center, Germantown, TN, spoke with the Journal of Clinical Pathways at the ASCO 2023 Annual Meeting about his study on inequities in next-generation sequencing testing by race/ethnicity...
Dr Gregory Vidal, Breast Medical Oncologist, West Cancer Center, Germantown, TN, spoke with the Journal of Clinical Pathways at the ASCO 2023 Annual Meeting about his study on inequities in next-generation sequencing testing by race/ethnicity...
Dr Gregory Vidal, Breast Medical...
06/07/2023
Journal of Clinical Pathways
Conference Coverage
Cost-Effectiveness of Adjuvant Osimertinib vs Placebo in NSCLC
06/02/2021
Study findings suggest adjuvant osimertinib is more cost-effective than placebo if one is willing to pay $317,119 more per QALY gained.
Study findings suggest adjuvant osimertinib is more cost-effective than placebo if one is willing to pay $317,119 more per QALY gained.
Study findings suggest adjuvant...
06/02/2021
Journal of Clinical Pathways
Conference Coverage
Treatment Patterns After EGFR-TKI and Platinum-Based Chemotherapy Discontinuation in Metastatic NSCLC
04/16/2021
Study results show that immunotherapy is the most common next line of therapy after discontinuation of an EGFR-TKI and platinum-based chemotherapy for metastatic NSCLC.
Study results show that immunotherapy is the most common next line of therapy after discontinuation of an EGFR-TKI and platinum-based chemotherapy for metastatic NSCLC.
Study results show that...
04/16/2021
Journal of Clinical Pathways
Conference Coverage
Biomarker Testing-Guided Treatment Improves Outcomes in Advanced or Metastatic NSCLC
04/07/2021
Treatment guided by biomarker testing is associated with improved survival outcomes in patients with advanced or metastatic NSCLC.
Treatment guided by biomarker testing is associated with improved survival outcomes in patients with advanced or metastatic NSCLC.
Treatment guided by biomarker...
04/07/2021
Journal of Clinical Pathways
Conference Coverage
Real-World Use of Pembrolizumab Plus Chemotherapy for NSCLC
04/06/2021
04/06/2021
Journal of Clinical Pathways
Conference Coverage
Delayed EGFR Testing in Early-Stage NSCLC Linked to Increased Health Care Utilization and Cost Burden
04/01/2025
Juliet Gallagher
Timely molecular testing is essential for guiding targeted treatment in patients with early-stage non-small cell lung cancer (eNSCLC), particularly those with EGFR mutations. Findings presented at the 2025 National Comprehensive Cancer...
Timely molecular testing is essential for guiding targeted treatment in patients with early-stage non-small cell lung cancer (eNSCLC), particularly those with EGFR mutations. Findings presented at the 2025 National Comprehensive Cancer...
Timely molecular testing is...
04/01/2025
Journal of Clinical Pathways
Conference Coverage
Study Explores Early Palliative Care Referral Patterns and Outcomes in SCLC
04/01/2025
Juliet Gallagher
At the 2025 National Comprehensive Cancer Network (NCCN) Annual Conference, researchers presented findings from a retrospective study evaluating timing of palliative care referral and associated outcomes among patients with small cell lung...
At the 2025 National Comprehensive Cancer Network (NCCN) Annual Conference, researchers presented findings from a retrospective study evaluating timing of palliative care referral and associated outcomes among patients with small cell lung...
At the 2025 National...
04/01/2025
Journal of Clinical Pathways
Conference Coverage
EHR-Embedded CDS Tool Enhances Specialty Drug Management in Oncology
03/28/2025
Juliet Gallagher
A retrospective study presented at the 2025 National Comprehensive Cancer Network (NCCN) Annual Conference evaluated how embedding a clinical decision support (CDS) tool within the electronic health record (EHR) can enhance specialty drug...
A retrospective study presented at the 2025 National Comprehensive Cancer Network (NCCN) Annual Conference evaluated how embedding a clinical decision support (CDS) tool within the electronic health record (EHR) can enhance specialty drug...
A retrospective study presented...
03/28/2025
Journal of Clinical Pathways
Conference Coverage
Patient-Centered Insights into Treatment Preferences for Locally Advanced and Metastatic NSCLC
03/28/2025
Juliet Gallagher
New research presented at the 2025 National Comprehensive Cancer Network (NCCN) Annual Conference sheds light on how patients with advanced or metastatic non-small cell lung cancer (aNSCLC or mNSCLC) approach treatment decision-making,...
New research presented at the 2025 National Comprehensive Cancer Network (NCCN) Annual Conference sheds light on how patients with advanced or metastatic non-small cell lung cancer (aNSCLC or mNSCLC) approach treatment decision-making,...
New research presented at the...
03/28/2025
Journal of Clinical Pathways
Headshot
Videos
The Role of ctDNA Clearance in RCC: Retrospective Analysis and Clinical Implications
02/13/2025
Adanma Ayanambakkam, MD
In this interview, Adanma Ayanambakkam, MD, discusses his study on the use of circulating tumor DNA (ctDNA) clearance as a biomarker in renal cell carcinoma (RCC), highlighting findings from a single-institution retrospective study and its...
In this interview, Adanma Ayanambakkam, MD, discusses his study on the use of circulating tumor DNA (ctDNA) clearance as a biomarker in renal cell carcinoma (RCC), highlighting findings from a single-institution retrospective study and its...
In this interview, Adanma...
02/13/2025
Journal of Clinical Pathways
Thierry Andre, MD, St Antoine Hospital
Videos
Nivolumab Plus Ipilimumab Combination for Microsatellite Instability-High, Mismatch Repair-Deficient Metastatic Colorectal Cancer
02/04/2025
Thierry André, MD
Thierry Andre, MD, describes results from the CheckMate 8HW trial which evaluated nivolumab plus ipilimumab compared with nivolumab monotherapy among patients with MSI-H/dMMR metastatic colorectal cancer.
Thierry Andre, MD, describes results from the CheckMate 8HW trial which evaluated nivolumab plus ipilimumab compared with nivolumab monotherapy among patients with MSI-H/dMMR metastatic colorectal cancer.
Thierry Andre, MD, describes...
02/04/2025
Oncology
Lisa Herms
Conference Coverage
Impact of Bispecific Antibodies on Treatment Patterns and Patient Characteristics in Multiple Myeloma
12/19/2024
Lisa Herms, PhD
Learn about the real-world utilization of bispecific antibodies for relapsed/refractory multiple myeloma in the US community oncology setting, showing promising results in patient characteristics and uptake, with potential impact on patient...
Learn about the real-world utilization of bispecific antibodies for relapsed/refractory multiple myeloma in the US community oncology setting, showing promising results in patient characteristics and uptake, with potential impact on patient...
Learn about the real-world...
12/19/2024
Journal of Clinical Pathways
Videos
Driving Innovation in Cancer Care: The Future of Value-Based Care in Oncology
12/04/2024
Gordon Kuntz
In this interview, Gordon Kuntz discusses the Delphi Method, a Predictable Cost of Care Model developed by the Predictable Cost of Care Working Group that enhances oncology market access strategies by standardizing and broadening the economic...
In this interview, Gordon Kuntz discusses the Delphi Method, a Predictable Cost of Care Model developed by the Predictable Cost of Care Working Group that enhances oncology market access strategies by standardizing and broadening the economic...
In this interview, Gordon Kuntz...
12/04/2024
Journal of Clinical Pathways
Videos
Building Consensus for Predictable Cancer Care Costs: Applying the Delphi Method to Multidisciplinary Stakeholder Collaboration
12/02/2024
Carole Tremonti, RN, MBA
In this interview, Carole Tremonti, RN, MBA, discusses the critical role of clinical pathways in equitable cancer care, the application of the Delphi Method by the Predictable Cost of Care Working Group to foster multidisciplinary...
In this interview, Carole Tremonti, RN, MBA, discusses the critical role of clinical pathways in equitable cancer care, the application of the Delphi Method by the Predictable Cost of Care Working Group to foster multidisciplinary...
In this interview, Carole...
12/02/2024
Journal of Clinical Pathways
Videos
The Evolving Role of Pharmacists in Custom Pathway Implementation
11/25/2024
Rebecca Maniago, PharmD, BCOP
In this interview, Rebecca Maniago, PharmD, discusses the complexities of implementing custom clinical pathways, emphasizing the need for clear goals, robust resources, and ongoing updates, while highlighting the pivotal role of pharmacists...
In this interview, Rebecca Maniago, PharmD, discusses the complexities of implementing custom clinical pathways, emphasizing the need for clear goals, robust resources, and ongoing updates, while highlighting the pivotal role of pharmacists...
In this interview, Rebecca...
11/25/2024
Journal of Clinical Pathways
JCP January/February 2025

Current Issue

February 2025
Volume 11
Issue 1
Current Issue
Issue Archive

Special Reports

Page 1
Special Report
Predictable Cost of Care Model for Treatment Decisions: Working Group Consensus Statements for Metastatic Non-Small Cell Lung Cancer
02/19/2025
Edward Arrowsmith, MD; Vishnukamal Golla, MD, MPH; Rhonda Henschel, MBA; Andrew Hertler, MD, FACP; David Jackman, MD; Gordon Kuntz; Olaf Lodbrok, MS, MBA; Carole Tremonti, RN, MBA; Lalan Wilfong, MD
The Predictable Cost of Care Working Group developed a model that can be used by various entities evaluating the impact of treatment on the total cost of care.
The Predictable Cost of Care Working Group developed a model that can be used by various entities evaluating the impact of treatment on the total cost of care.
The Predictable Cost of Care...
02/19/2025
Journal of Clinical Pathways
JCP Special Report
Recommendations for Creating an Oncology Clinical Pathways Framework Tool Based on Payer, Provider, and Patient Priorities: Findings From the 2021 Care Pathways Working Group
05/20/2022
Robin T. Zon, MD, FACP, FASCO; Gordon Kuntz; Winston Wong, PharmD
The Journal of Clinical Pathways convened the 2021 Care Pathways Working Group to identify and reconcile the different pathway drivers for each stakeholder now and five years into the future, creating a framework tool based on oncology care...
The Journal of Clinical Pathways convened the 2021 Care Pathways Working Group to identify and reconcile the different pathway drivers for each stakeholder now and five years into the future, creating a framework tool based on oncology care...
The Journal of Clinical Pathways...
05/20/2022
Journal of Clinical Pathways

Subscribe

Journal of Clinical Pathways Newsletter

Recent Stories

Conference Coverage
Patient-Centered Insights into Treatment Preferences for Locally Advanced and Metastatic NSCLC
03/28/2025
Juliet Gallagher
New research presented at the 2025 National Comprehensive Cancer Network (NCCN) Annual Conference sheds light on how patients with advanced or metastatic non-small cell lung cancer (aNSCLC or mNSCLC) approach treatment decision-making,...
New research presented at the 2025 National Comprehensive Cancer Network (NCCN) Annual Conference sheds light on how patients with advanced or metastatic non-small cell lung cancer (aNSCLC or mNSCLC) approach treatment decision-making,...
New research presented at the...
03/28/2025
Journal of Clinical Pathways
News
Radiomics and AI Advance NSCLC Staging Precision
03/10/2025
Juliet Gallagher
A recent study published in Cancers explores the potential of artificial intelligence (AI) to enhance the preliminary staging of non-small cell lung cancer (NSCLC) using computed tomography (CT) imaging.
A recent study published in Cancers explores the potential of artificial intelligence (AI) to enhance the preliminary staging of non-small cell lung cancer (NSCLC) using computed tomography (CT) imaging.
A recent study published in...
03/10/2025
Journal of Clinical Pathways
News
Machine Learning Identifies Key Genomic Markers to Predict CPI Outcomes in NSCLC
03/06/2025
Grace Taylor, MS, MA
A machine learning-driven study analyzing genomic data from patients with non-small cell lung cancer (NSCLC) reveals specific mutations and pathways that influence resistance to checkpoint inhibitor immunotherapy, offering potential targets...
A machine learning-driven study analyzing genomic data from patients with non-small cell lung cancer (NSCLC) reveals specific mutations and pathways that influence resistance to checkpoint inhibitor immunotherapy, offering potential targets...
A machine learning-driven study...
03/06/2025
Journal of Clinical Pathways
News
Evaluating Cost-Effectiveness of First-Line Cemiplimab Therapy in Advanced NSCLC
03/05/2025
Juliet Gallagher
A recent cost-effectiveness analysis published in Journal of Managed Care & Specialty Pharmacy comparing cemiplimab plus chemotherapy (CCT) with pembrolizumab plus chemotherapy (PCT) as first-line treatment for advanced non-small cell lung...
A recent cost-effectiveness analysis published in Journal of Managed Care & Specialty Pharmacy comparing cemiplimab plus chemotherapy (CCT) with pembrolizumab plus chemotherapy (PCT) as first-line treatment for advanced non-small cell lung...
A recent cost-effectiveness...
03/05/2025
Journal of Clinical Pathways
News
Durvalumab Immunotherapy Shows Survival Benefit but Fails Cost-Effectiveness in Key Markets
02/13/2025
Lisa Kuhns, PhD, MD
Durvalumab immunotherapy improves survival in unresectable stage III non-small cell lung cancer (NSCLC), but its high cost makes it prohibitive globally under current pricing models, according to study results published in JAMA Network Open.
Durvalumab immunotherapy improves survival in unresectable stage III non-small cell lung cancer (NSCLC), but its high cost makes it prohibitive globally under current pricing models, according to study results published in JAMA Network Open.
Durvalumab immunotherapy...
02/13/2025
Journal of Clinical Pathways

Specialties

Events

Year Round Education

HMP Global Products

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2025 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Term of Use